(Reuters) -A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly’s popular weight-loss drug Zepbound in the U.S.
The decision was filed late on Wednesday in response to a lawsuit brought by a compounding industry group that challenged the U.S. Food and Drug Administration’s decision to bar those copies.
(Reporting by Patrick Wingrove)
Comments